BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36038884)

  • 1. Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
    Berrino E; Annaratone L; Bellomo SE; Ferrero G; Gagliardi A; Bragoni A; Grassini D; Guarrera S; Parlato C; Casorzo L; Panero M; Sarotto I; Giordano S; Cereda M; Montemurro F; Ponzone R; Crosetto N; Naccarati A; Sapino A; Marchiò C
    Genome Med; 2022 Aug; 14(1):98. PubMed ID: 36038884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
    Freitag CE; Mei P; Wei L; Parwani AV; Li Z
    Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
    Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
    JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
    Verschoor N; Smid M; Jager A; Sleijfer S; Wilting SM; Martens JWM
    Breast Cancer Res; 2023 Nov; 25(1):145. PubMed ID: 37968696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.
    Giannoudis A; Sartori A; Eastoe L; Zakaria R; Charlton C; Hickson N; Platt-Higgins A; Rudland PS; Irwin D; Jenkinson MD; Palmieri C
    Breast Cancer Res Treat; 2021 Nov; 190(2):241-253. PubMed ID: 34499316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
    Aftimos P; Oliveira M; Irrthum A; Fumagalli D; Sotiriou C; Gal-Yam EN; Robson ME; Ndozeng J; Di Leo A; Ciruelos EM; de Azambuja E; Viale G; Scheepers ED; Curigliano G; Bliss JM; Reis-Filho JS; Colleoni M; Balic M; Cardoso F; Albanell J; Duhem C; Marreaud S; Romagnoli D; Rojas B; Gombos A; Wildiers H; Guerrero-Zotano A; Hall P; Bonetti A; Larsson KF; Degiorgis M; Khodaverdi S; Greil R; Sverrisdóttir Á; Paoli M; Seyll E; Loibl S; Linderholm B; Zoppoli G; Davidson NE; Johannsson OT; Bedard PL; Loi S; Knox S; Cameron DA; Harbeck N; Montoya ML; Brandão M; Vingiani A; Caballero C; Hilbers FS; Yates LR; Benelli M; Venet D; Piccart MJ
    Cancer Discov; 2021 Nov; 11(11):2796-2811. PubMed ID: 34183353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
    Miyashita M; Bell JSK; Wenric S; Karaesmen E; Rhead B; Kase M; Kaneva K; De La Vega FM; Zheng Y; Yoshimatsu TF; Khramtsova G; Liu F; Zhao F; Howard FM; Nanda R; Beaubier N; White KP; Huo D; Olopade OI
    Breast Cancer Res; 2023 May; 25(1):58. PubMed ID: 37231433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification of HER2-negative breast cancers by
    Loh JW; Lim AH; Chan JY; Yap YS
    Ther Adv Med Oncol; 2023; 15():17588359231206259. PubMed ID: 37920257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
    Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X
    Front Oncol; 2020; 10():1023. PubMed ID: 32695676
    [No Abstract]   [Full Text] [Related]  

  • 12. The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
    Marchiò C; Dell'Orto P; Annaratone L; Geyer FC; Venesio T; Berrino E; Verdun di Cantogno L; Garofoli A; Rangel N; Casorzo L; dell'Aglio C; Gugliotta P; Trisolini E; Beano A; Pietribiasi F; Orlassino R; Cassoni P; Pich A; Montemurro F; Mottolese M; Vincent-Salomon A; Penault-Llorca F; Medico E; Ng CKY; Viale G; Sapino A
    Am J Surg Pathol; 2018 Sep; 42(9):1190-1200. PubMed ID: 29975246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
    Tarantino P; Gupta H; Hughes ME; Files J; Strauss S; Kirkner G; Feeney AM; Li Y; Garrido-Castro AC; Barroso-Sousa R; Bychkovsky BL; DiLascio S; Sholl L; MacConaill L; Lindeman N; Johnson BE; Meyerson M; Jeselsohn R; Qiu X; Li R; Long H; Winer EP; Dillon D; Curigliano G; Cherniack AD; Tolaney SM; Lin NU
    Nat Commun; 2023 Nov; 14(1):7496. PubMed ID: 37980405
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Vahdatinia M; Derakhshan F; Da Cruz Paula A; Dopeso H; Marra A; Gazzo AM; Brown D; Selenica P; Ross DS; Razavi P; Zhang H; Weigelt B; Wen HY; Brogi E; Reis-Filho JS; Pareja F
    J Clin Pathol; 2023 Dec; 77(1):40-45. PubMed ID: 36323507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
    Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
    PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome profiling of ERBB2-amplified breast cancers.
    Sircoulomb F; Bekhouche I; Finetti P; Adélaïde J; Ben Hamida A; Bonansea J; Raynaud S; Innocenti C; Charafe-Jauffret E; Tarpin C; Ben Ayed F; Viens P; Jacquemier J; Bertucci F; Birnbaum D; Chaffanet M
    BMC Cancer; 2010 Oct; 10():539. PubMed ID: 20932292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.